ETHINYLESTRADIOL /DESOGESTREL (Bimizza®- 20/150, Gedarel® 20/150, Gedarel® 30/150)
Clinical Indication
Oral CHC
Comments
THIRD CHOICE
Gedarel®: Specify strength when prescribing (two formulations available)
Date of classification
September 2025
Green
Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.